ArticleArtificial organs2014
Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?
Article in Artificial organs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 82 citations in OpenAlex.
- Rethinking cardiovascular risk: The emerging role of lipoprotein(a) screening.American journal of preventive cardiology · 2025Review
- Changing from lipoprotein apheresis to evolocumab treatment lowers circulating levels of arachidonic acid and oxylipins.Atherosclerosis plus · 2024Article
- Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolemia: an expert consensus statement from ERKNet and ESPN.medRxiv : the preprint server for health sciences · 2023Article
- Is Lipoprotein(a) Clinically Actionable with Today's Evidence? The Answer is Yes.Current cardiology reports · 2023Review
- Apheresis: What Should a Clinician Know?Current atherosclerosis reports · 2023Review
- Therapeutic Apheresis for Management of Lp(a) Hyperlipoproteinemia.Current atherosclerosis reports · 2020Review
- Lipoprotein(a) Lowering-From Lipoprotein Apheresis to Antisense Oligonucleotide Approach.Journal of clinical medicine · 2020Review
- Lipoprotein(a) Elevation: A New Diagnostic Code with Relevance to Service Members and Veterans.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2019Article
- Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice.Current atherosclerosis reports · 2019Review
- Current Role of Lipoprotein Apheresis.Current atherosclerosis reports · 2019Review
- Hyperlipoproteinaemia(a) - apheresis and emerging therapies.Clinical research in cardiology supplements · 2017Review
- Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).Clinical research in cardiology supplements · 2017Review
- The Italian Consensus Conferences on low density lipoprotein-cholesterol apheresis.Blood transfusion = Trasfusione del sangue · 2017Article
- Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.Current atherosclerosis reports · 2016Review
- Lipoprotein apheresis to treat elevated lipoprotein (a).Journal of lipid research · 2016Review
- HyperLp(a)lipoproteinaemia: unmet need of diagnosis and treatment?Blood transfusion = Trasfusione del sangue · 2016Article
- Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review.Blood transfusion = Trasfusione del sangue · 2016Review
- Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection.Medical devices (Auckland, N.Z.) · 2016Review
- Cardiovascular risk factors in the antiphospholipid syndrome.Journal of immunology research · 2014Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated lipoprotein(a) (Lp(a)) is known as an independent risk factor for atherosclerosis and cardiovascular events. Regular lipid apheresis decreases elevated Lp(a) concentrations. However, there is a lack of reliable data regarding the effect of lipid apheresis on cardiovascular endpoints. To assess the effects of apheresis, we compared the occurrence of cardiovascular events in 37 patients treated regularly with lipid apheresis at the time periods of preinitiation of apheresis and during apheresis treatment. A retrospective analysis of 37 patients (35 men and two women; aged 58 years ± 11 [mean ± standard deviation]; body mass index 26 kg/m(2) ± 3; low-density lipoprotein (LDL)-cholesterol before apheresis 84 mg/dL ± 21; Lp(a) before apheresis 112 mg/dL ± 34) treated regularly with lipid apheresis was performed. Patients' medical records were screened for cardiovascular events at the preapheresis and during apheresis periods. Apheresis led to a significant reduction of lipid levels (LDL cholesterol -60%; Lp(a) -68%) measured after apheresis. The event-free survival rate after 1 year in the preapheresis period was 38% (22-54%, 95% confidence interval [CI]) vs. 75% (61-89%, 95% CI) in the during-apheresis period with a statistically significant difference (P < 0.0001). Apheresis seems to lower the progression of atherosclerosis leading to a reduced number of cardiovascular events in hyperlipoproteinemia(a). Because prospective and controlled trials are lacking, the therapeutic effectiveness of lipid apheresis can only be estimated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.